Company Updates
First Graphene Experiences Significant Share Price Growth of over 60% since December
First Graphene (ASX: FGR) has led graphene research in Australia during 2017.
Fusion Musictech Raises $1.7M in FY17; Now Selling in the USA
The world’s most innovative electric guitar has launched and is selling in the USA market.
LifeArt Revolutionising the UK Coffin Market
The UK LifeArt innovation centre, reverses a world-wide trend seeing coffin manufacturers closing, was opened by the Duke of Gloucester.
SUDA Pharmaceuticals Signs Licence & Supply Deals for ZolpiMist™ & Feasibility & Option Agreement with Pfizer
Solid progress in business development and R&D.
Flamingo AI Raises $10M Through Placement
Flamingo AI has raised $10,000,000 in a successful capital raise at an issue price of 6.2 cents for each share.
WYZA Raises $525k in 2017 & Forms Joint Venture
WYZA Limited has raised $525,000 in the calendar year of 2017, added a new Company Secretary & CFO, and two non-executive directors, and
Intermin Resources (ASX: IRC) Update on Teal Operations
Intermin Resources Limited is pleased to divulge that the haulage of the first ore that constitutes about 24,000t has commenced.
iFast Corporation’s FSMOne Account Lists US Securities
iFast Singapore opens its doors for US-listed stocks. With FSMOne, the current offering at a reasonably catchy rate of 0.08% subject to at least US$8.80 per trade.
SUDA’s Licensee Lodges Application for Short-Term Treatment of Insomnia
SUDA’s licensee Teva started the submission for the ZolpiMist approval. ZolpiMist is the promising drug of choice for short-term treatment of insomnia due to its enhanced distinctive qualities.
Backed By Leading Investment Groups and Family Offices
